Coroner concerned staffing levels on 'under pressure' hospital ward led to death
A CORONER has urged a Cumbrian NHS Trust to take action after it emerged that an 'understaffed and under pressure' hospital ward may have been a factor in a woman's death.
Sarah Kathleen Hill, 78, from Dalston, died in the Cumberland Infirmary on November 8, 2024, after undergoing an elective procedure to remove gallstones.
Mrs Hill underwent the procedure, an endoscopic retrograde cholangiopancreatography (ERCP) on November 5.
The procedure was partially successful, though the largest stone remained, and the procedure 'abandoned', according to coroner, Margaret Taylor.
Ms Taylor sent a Prevention of Future Deaths report to the North Cumberland Integrated Care NHS Trust (NCIC) with concerns relating to the care of Mrs Hill after the procedure, during which her condition deteriorated, leading to her death.
Ms Taylor wrote that Mrs Hill complained of 'nausea, vomiting and pain' post-operatively, and she was subjected to a CT scan to rule out pathological issues.
The CT showed no evidence of perforation, but Mrs Hill was admitted for pancreatitis, a 'recognised complication of ERCP'.
On November 6, her condition worsened, and on November 7, Mrs Hill collapsed while going to the toilet.
A further CT scan on November 7 showed 'significant worsening' of her pancreatitis and other complications.
The surgical team decided Mrs Hill was 'not for escalation', and at 5pm, she had an unwitnessed fall 'at a time she was meant to be closely observed'.
Mrs Hill became unresponsive shortly afterwards, going into cardiac arrest, and blood results showed she had developed multi organ failure.
Mrs Hill died in the early hours of November 8.
Ms Taylor wrote to NCIC requesting action to be taken in relation to five areas of concern during this period.
She stated: "There was a lack of evidence that suggested appropriate falls risk assessments had been undertaken and a failure to report falls/collapses on the ward
"There was a lack of documentation about the use of cot sides and the placement of the call bell within Mrs Hill's reach .
"There was a lack of frequent recorded observations necessitated by Mrs Hill's deteriorating condition.
"Mrs Hill was placed in a side room where she was not easily observed without consideration given for the need for additional monitoring which led to her being left alone for extended periods of time.
"I was advised that the ward was understaffed and under pressure."
"I was told that despite this being appropriately escalated, nurses were caring for ten patients when the expected allocation would be six patients for each nurse on duty .
READ MORE: Inquest to ask why pensioner's fatal injury went undetected by two hospitals
READ MORE: Inquest opens into death of mountain biker who fell on Lake District trail
"No further help was provided to the ward following escalation.
"The evidence presented to me was that this was not an unusual situation on the ward."
NCIC is obliged to respond to the concerns raised by July 22, 2025.
A spokesperson for NCIC said: "We would like to express our heartfelt condolences to the family and loved ones of Mrs Hill.
"We fully accept the findings from the coroner and have implemented the learning points raised in the report."

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Associated Press
31 minutes ago
- Associated Press
‘Our Journey with Lobular Breast Cancer' documentary to premiere at Raindance Film Festival
LONDON, UNITED KINGDOM, June 24, 2025 / / -- A new documentary highlighting the campaign for research funding into lobular breast cancer will premiere at the 33rd Raindance Film Festival in London this June. 'Our Journey with Lobular Breast Cancer' tells the story of the Lobular Moon Shot Project, launched in 2023 by Dr Susan Michaelis. The campaign has won support from 365 MPs in the House of Commons calling for a five-year, £20 million research programme into invasive lobular breast cancer, the second most common form of breast cancer in the UK. Invasive lobular breast cancer is difficult to detect with standard mammograms or ultrasounds and currently has no treatment tailored to its unique biology. With an estimated 3.75 million diagnoses worldwide over the next decade, the disease behaves differently from the more common ductal breast cancer and remains an urgent clinical need. Produced by Fact Not Fiction Films, the documentary will be screened at Vue Piccadilly. The world premiere is scheduled for 5pm on Tuesday 24 June, followed by an additional screening at 12.30pm on Wednesday 25 June. Director Tristan Loraine, nominated for Best Director UK Feature, has two films showing at the festival this year. The Lobular Moon Shot Project aims to raise awareness and secure public funding for a major research initiative led by the Manchester Breast Centre at the University of Manchester. The centre will collaborate with other institutions to deepen global understanding of the disease and develop targeted treatments. Campaigners say the project's estimated £20 million budget over five years is vital to accelerate progress. - Tickets and more information are available on the Raindance website. - You can access the JustGiving fundraiser to make a donation. About The Lobular Moon Shot Project The Lobular Moon Shot Project was established in 2023 to address a critical gap in breast cancer research. Its mission is to secure funding for vital studies that will improve understanding of invasive lobular breast cancer (ILC) and support the development of targeted treatments. Alongside fundraising efforts, the project works to build political support to ensure governments provide dedicated funding for research into this disease. Although some research is currently underway worldwide, a coordinated large-scale study is urgently needed. The project calls for a £20 million investment over five years to accelerate progress. With approximately 1,000 people diagnosed globally every day—including 22 daily cases in the UK—the Lobular Moon Shot Project advocates for a 'moon shot' level of commitment to advance research and improve outcomes for those affected. About Fact Not Fiction Films Fact Not Fiction Films, founded in 2006 and based in West Sussex, England, is an award-winning production company specialising in documentaries, feature films, and corporate videos. The company focuses on stories that explore important public issues, combining creative passion with technical expertise and high-quality production standards. Its work is suitable for corporate clients, broadcast audiences, and theatrical releases. Fact Not Fiction Films is committed to creating engaging and impactful films that raise awareness of key topics and contribute to positive social change. Press Fact Not Fiction Films [email protected] Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Medscape
31 minutes ago
- Medscape
Psilocybin Safe, Effective for TRD: Phase 3 Data
A single dose of a synthetic form of psilocybin known as COMP360 (Compass Pathways) is both statistically significant and clinically meaningful in reducing treatment-resistant depression (TRD) in a new phase 3 trial, its manufacturer announced in a press release. Topline results from the ongoing COMP005 trial showed that a single 25-mg dose of the investigational drug was associated with a greater reduction in symptom severity on the Montgomery-Åsberg Depression Rating Scale (MADRS) at 6 weeks than matching placebo, meeting the study's primary endpoint. Additionally, there were 'no unexpected safety findings and no clinically meaningful imbalance in suicidal ideation between treatment and placebo arms,' the company added. This is 'the first study of an investigational, synthetic psilocybin, and the first classic psychedelic, to report phase 3 efficacy data,' the company said. The results are important for patients with TRD who do not respond to currently approved and available treatment options, Guy Goodwin, MD, chief medical officer at Compass, said in the release. 'This achievement provides hope that they can finally receive appropriate care and live the life they deserve,' Goodwin added. Ongoing Research COMP360 is a synthetic and proprietary formulation of psilocybin. As reported by Medscape Medical News, results presented at the 2023 European Psychiatric Association Congress from a phase 2 study assessing a single 25-mg dose of the drug were associated with improvements of core symptoms in patients with TRD. It has also appeared to be effective for bipolar depression and for anorexia nervosa in two separate small studies. COMP005 is the first of two ongoing and parallel-running phase 3 trials assessing the investigational drug. In it, 258 patients with TRD were enrolled across 32 US sites and randomly assigned to receive one administration of either the active drug at a dose of 25 mg or matching placebo. The newly released results are from the first part of the trial, which included blinding through 6 weeks. From baseline to 6 weeks, the participants who received the active treatment had a significantly greater reduction in symptom severity on the MADRS compared to those who received placebo ( P < .001). In addition, there was a mean score treatment difference of -3.6 (95% CI, -5.7 to -1.5), demonstrating a clinically meaningful reduction, the company noted. The trial's data, which were reviewed by an independent Data Safety Monitoring Board, showed no new or unexpected safety findings and were consistent with those from previous COMP360 studies. Part 2 of the ongoing trial will be evaluating results blinded through week 26, and part 3 will contain open-label treatment from week 26 to week 52. 'We eagerly anticipate further insights once we have the full dataset,' Kabir Nath, Compass' chief executive officer, said in the release. For now, the company reported that it is planning to discuss these preliminary results with the US Food and Drug Administration. In addition, the ongoing phase 3 COMP006 trial is aiming to enroll 568 participants from North America and Europe and will assess two fixed doses of the active treatment. Compass is expecting to receive 26-week data during the second half of 2026.
Yahoo
an hour ago
- Yahoo
Overlooking sexual harassment against health staff ‘risks patient safety'
Healthcare staff who 'turn a blind eye' to colleagues being sexually harassed at work face putting patient safety at risk, doctors have warned. Medics claim that overlooking these incidents allows other toxic behaviours 'to perpetuate'. It comes as members of the British Medical Association (BMA) called for NHS trusts to include active bystander training – which aims to equip people with the skills to challenge unacceptable conduct – in mandatory training programmes. Delegates at the union's annual representative meeting (ARM) in Liverpool also voted for the BMA to lobby for a national anonymous reporting system for victims of sexual harassment. Dr Helen Neary, co-chairwoman of the BMA consultants committee, said: 'People are bystanders at all levels, and a working culture that turns a blind eye to this behaviour is also a risk to patient safety, enabling other poor behaviours to perpetuate.' The motion urged NHS organisations to probe allegations of sexual misconduct using trained investigators external to the trust. Dr Neary added: 'No one should feel unsafe at work. Yet the appalling truth is that doctors, disproportionately women, are still subject to sexual harassment, abuse and assault in the workplace – often by their fellow doctors. This has to stop. 'Not only is it obviously completely unacceptable and has a devastating impact on victims, but also affects the quality of care and workforce capacity as poor behaviours will do nothing to retain staff in the NHS.' In March, the latest NHS staff survey found one in 12 (8.82%) of workers were the target of unwanted sexual behaviour such as offensive comments, touching and assaults. The proportion was similar to that reported in 2023 (8.79%) when the question was first asked as part of the survey. Last October, NHS England launched a new national sexual misconduct policy framework to ensure trusts had robust policies in place for staff to report incidents. Speaking to delegates at the BMA ARM in Liverpool, Professor Bhairavi Sapra said that while the framework is a 'very welcome first step', it is not mandatory. 'It is up to individual employers to adopt it, and even then, perpetrators can simply move on from one employer to another without accountability for those in positions of power to prevent this behaviour,' she added. 'Worse still, there is no national reporting mechanism. That means if someone wants to report an incident months later in a different workplace, they face an uphill battle, often alone. 'Survivors have told us why they don't come forward. They fear being told they're overreacting. 'They fear retaliation or reputational damage. They fear nothing will change, and sadly, they are not wrong. 'Investigations, when they do happen, are rarely trauma informed, often the process itself can feel like another form of harm.' Dr Neary said: 'As the trade union and professional association for all doctors in the UK – from those beginning their careers as medical students to retirement and beyond – the BMA welcomes the legal obligation placed on the NHS to protect employees from sexual harassment. 'This vote makes some excellent suggestions on how this work can go further, including anonymous reporting, that will encourage those concerned about coming forward to do so, and better equipping doctors on how they can support colleagues when they witness sexual harassment at work.' Prof Sapra also claimed the 'power imbalance' in the medical profession is 'stark', adding: 'Junior staff rely on senior medical staff for training, for references and for their very careers. 'That dependency makes them especially vulnerable and often silent.' An NHS England spokesperson said: 'It is totally unacceptable that NHS staff experience sexual misconduct or harassment at work – this behaviour has no place in the health service, and all organisations must take robust and compassionate action to prevent it. 'The NHS Sexual Safety Charter has been adopted by every Integrated Care Board and NHS Trust in England, which encourages consideration of external, independent investigators in complex or sensitive cases – and all NHS organisations should ensure that those leading these processes are properly trained to handle them with the seriousness and sensitivity they require.'